1002114-29-5

Basic information

• Product Name: 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid
• Synonyms: 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid
• CAS NO: 1002114-29-5
• Molecular Weight: 318.547
• Mol File: 1002114-29-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid(1002114-29-5)
• EPA Substance Registry System: 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid(1002114-29-5)

Safety Data

• Hazardous Substances Data: 1002114-29-5(Hazardous Substances Data)

Upstream product

• 825619-04-3 4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxylic acid 

Downstream Products

• 844443-90-9 tert-butyl 4-(4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamido)piperidine-1-carboxylate 

Relevant articles and documents

PHARMACEUTICAL COMBINATIONS

The invention provides combinations of an ancillary compound of the formula (0): and a compound of the formula (I'): Also provided are crystalline forms of the constituent compounds, methods for making them and their uses in treating cancers.

PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT

The invention provides a combination comprising (or consisting essentially of) an ancillary compound and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein: R1 is 2,6-dichlorophenyl; R2a and R

COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS

The invention provides a combination of a compound having the formula (0) and two or more further anti-cancer agents: or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C=O, NR9(C=O) or 0(C=O) wherein R9 is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1 , 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).